BMJ22h
Transitions to different patterns of interstitial lung disease in scleroderma with and without treatment
Objectives The aim is to investigate whether the 12-month quantitative changes in high-resolution CT (HRCT) measures of interstitial lung disease (ILD) are different, and to understand how they change ...
BMJ1d
Safety and efficacy of vaccination against hepatitis B in patients with rheumatoid arthritis
Department of Rheumatology, Tel Aviv “Sourasky” Medical Centre and the “Sackler” Faculty of Medicine, University of Tel Aviv, Israel Correspondence to: Dr O Elkayam, Department of Rheumatology, Tel ...
BMJ1d
Standardisation of myositis-specific antibodies: where are we today?
With interest we read the recent article by Espinosa-Ortega et al 1 comparing a line immunoassay (LIA) and immunoprecipitation (IP) for the detection of autoantibodies associated with idiopathic ...
BMJ2d
Osteoarthritic bone marrow lesions almost exclusively colocate with denuded cartilage: a 3D study using data from the Osteoarthritis Initiative
4 Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK Correspondence to Professor Philip G Conaghan, Leeds Institute of Rheumatic and Musculoskeletal Medicine, ...
BMJ2d
Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)
Aims Treating to low disease activity is routine in rheumatoid arthritis, but no comparable goal has been defined for systemic lupus erythematosus (SLE). We sought to define and validate a Lupus Low ...
BMJ3d
Treatment of early oligoarticular psoriatic arthritis with apremilast: primary outcomes at week 16 from the FOREMOST randomised controlled trial
Objectives Oligoarticular psoriatic arthritis (PsA) is frequent but rarely studied. The objective was to assess the efficacy of apremilast in early oligoarticular PsA. Methods FOREMOST (NCT03747939) ...
BMJ4d
Bone development and inflammatory disease is regulated by AP-1 (Fos/Jun)
The Fos and Jun proteins are members of the AP-1 transcription factor complex, which is a central regulator for many cellular functions. This paper summarises the important functions of Fos proteins ...
BMJ6d
Psoriatic arthritis therapy: NSAIDs and traditional DMARDs
Non-steroidal anti-inflammatory drugs (NSAIDs) and traditional disease modifying antirheumatic drugs (DMARDs) are widely used in the treatment of psoriatic arthritis (PsA), but this is based more upon ...
BMJ6d
The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation
Correspondence to Professor Monika Østensen, National Service for Pregnancy and Rheumatic Diseases, Department of Rheumatology, Trondheim University Hospital, Trondheim 7006, Norway; ...
BMJ6d
Is the epidemiology of rheumatoid arthritis changing? Results from a population-based incidence study, 1985–2014
Objectives To examine trends in the incidence of rheumatoid arthritis (RA) from 2005 to 2014 overall and by serological status as compared with 1995–2004 and 1985–1994. Methods We evaluated RA ...
BMJ6d
Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors
12 University of California, San Francisco/Synarc, San Francisco, California, USA 13 Synarc, Inc, San Francisco, California, USA Objectives: To assess the efficacy and safety of abatacept in ...
BMJ10d
Burden of musculoskeletal disorders in the Eastern Mediterranean Region, 1990–2013: findings from the Global Burden of Disease Study 2013
Objectives We used findings from the Global Burden of Disease Study 2013 to report the burden of musculoskeletal disorders in the Eastern Mediterranean Region (EMR). Methods The burden of ...